Physician profile
Ruby Ramos
NPI 1518392448
$2,654.57
in general payments reported to CMS, 2019-2025
22 companies · $285 in 2025
The $285 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,378 · 2022: $300 · 2023: $460 · 2024: $232 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $977.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $976.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $260.44 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $227.32 | 2021-2023 | Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $177.08 | 2021-2022 | |
| Abbvie INC. | $167.43 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $162.14 | 2021-2022 | |
| Dexcom, INC. | $156.00 | 2022-2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $128.16 | 2023 | Rexulti |
| Alkermes, INC. | $125.11 | 2021 | |
| Braeburn INC. | $125.00 | 2025 | Brixadi |
| Vanda Pharmaceuticals INC. | $125.00 | 2024 | Fanapt |
| Glaxosmithkline, LLC. | $125.00 | 2021 | |
| Incyte Corporation | $114.91 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $110.01 | 2022 | |
| Exact Sciences Corporation | $105.77 | 2023-2024 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $99.40 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $92.01 | 2021-2024 | Ingrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.89 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.18 | 2021-2024 | Trintellix |
| Lilly USA, LLC | $59.31 | 2021-2023 | Jardiance |
| Lundbeck LLC | $56.67 | 2021 | |
| Boston Scientific Corporation | $35.32 | 2025 | Intracept |
| Amgen INC. | $24.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.